Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

45.73USD
18 Apr 2019
Change (% chg)

$-0.07 (-0.15%)
Prev Close
$45.80
Open
$46.00
Day's High
$46.00
Day's Low
$45.69
Volume
595,376
Avg. Vol
4,831,111
52-wk High
$63.69
52-wk Low
$44.30

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 29.30 32.55
EPS (TTM): 2.74 -- --
ROI: 18.60 14.23 13.83
ROE: 30.97 15.46 15.25

Deals of the day-Mergers and acquisitions

April 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

Apr 12 2019

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Apr 12 2019

UPDATE 2-Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK, April 12 Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Apr 12 2019

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK, April 12 Bristol-Myers Squibb Inc's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Apr 12 2019

Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Mar 29 2019

UPDATE 5-Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal

NEW YORK, March 29 Activist hedge fund Starboard Value LP on Friday abandoned a campaign to convince Bristol-Myers Squibb Co shareholders to vote down the drugmaker's proposed $74 billion takeover of biotech Celgene Corp after the two leading proxy advisory firms backed the deal.

Mar 29 2019

Starboard no longer urging investors to vote against Bristol-Celgene deal

BOSTON Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

Mar 29 2019

UPDATE 1-Starboard no longer urging investors to vote against Bristol-Celgene deal

BOSTON, March 29 Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

Mar 29 2019

Starboard no longer urging investors to vote against Bristol-Celgene deal

BOSTON, March 29 Activist hedge fund Starboard Value LP said on Friday it will no longer urge shareholders to oppose Bristol-Myers Squibb Co's plans to buy Celgene Corp, even though it thinks the deal is too risky and will vote its own shares against it.

Mar 29 2019

REFILE-Proxy advisor ISS backs Bristol takeover of Celgene

NEW YORK, March 29 Proxy advisory firm Institutional Shareholder Services on Friday recommended shareholders of drugmaker Bristol-Myers Squibb Co shareholders vote in favor of its proposed $74 billion takeover of rival Celgene Corp.

Mar 29 2019

Earnings vs. Estimates